Cantargia announces that the company has received an Intention to Grant notice from the European Patent Office for its patent application for the CAN04 product candidate.
The patent application, with application number 15714603.6, for which the EPO has issued an Intention to Grant notice, refers to the company’s CAN04 product candidate. The patent protects Cantargia’s CAN04 product candidate as a substance as well as its specific use for treatment of various forms of cancer. The notice of the Intention to Grant means that the EPO intends to approve the company’s patent application but that a number of administrative steps remain before a final notice of approval can be issued. The patent, when granted, provides protection of CAN04 in Europe until 2035.
In addition to Europe, Cantargia has submitted patent applications for CAN04 in several other territories, including the United States, Japan and China.
“The granting of a patent for our CAN04 product candidate is an important part of our efforts to build value in our portfolio”, Göran Forsberg, CEO of Cantargia, says. “We are very pleased that the examination of our application was completed quickly and that we have now taken a big step towards obtaining a patent in this large and important market”.